Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-13
2007-03-13
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
11094595
ABSTRACT:
A compound of the formula R1-Leu-A2-Val-A4-Ile-A6-Leu-A8-A9-A10-R2 SEQ ID NO: 1 or a pharmaceutically acceptable salt thereof, which disrupts the binding between the AF4 and AF9 proteins in mammalian cells in vitro and in vivo is useful in the treatment, prophylaxsis or diagnosis of various forms of leukemia. Such compounds are also useful in drug development for non-peptide mimics of the compounds of the invention.
REFERENCES:
patent: 6475753 (2002-11-01), Ruben et al.
Ayton et al., “Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins”,OncogeneSep. 10, 2001 20(40):5695-5707.
Biondi et al., “Biological and therapeutic aspects of infant leukemia”,BloodJul. 1, 2000 96(1):24-33.
Chessells et al., “Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party”,LeukemiaMay 2002 16(5):776-784.
Collins et al., “Mouse Af9 is a controller of embryo patterning, like M11, whose human homologue fuses with Af9 after chromosomal translocation in leukemia”,Mol. Cell. Biol.Oct. 2002 22(20):7313-7324.
Corral et al., “An M11-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes”,CellJun. 14, 1996 85(6):853-861.
Dimartino et al., “A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL”,BloodDec. 1, 2000 6(12):3887-3893.
Doty et al., “The leukemia-associated gene M11t1/ENL: characterization of a murine homolog and demonstration of an essential role in embryonic development”,Blood Cells Mol. Dis.May-Jun. 2002 28(3):407-417.
Erfurth et al., “MLL fusion partners AF4 and AF9 interact at subnuclear foci”,LeukemiaJan. 2004 18(1):92-102.
Felix et al., “Leukemia in infants”,OncologistJun. 1999 4(3):225-240.
Felix et al., “Pediatric Acute Lymphoblastic Leukemia: Challenges and Controversies in 2000”,Hematology2000 285-302.
Hess et al., “Defects in yolk sac hematopoiesis in M11-null embryos”,BloodSep. 1, 1997 90(5):1799-1806.
Isnard et al., “Altered lymphoid development in mice deficient for the mAF4 proto-oncogene”,BloodJul. 15, 2000 96(2):705-710.
Lavau et al., “Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL”,EMBO J.Jul. 16, 1997 16(14):4226-4237.
Lavau et al., “Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice”,Proc. Natl. Acad. Sci. USASep. 26, 2000 97(20):10984-10989.
Li et al., “AF4 encodes a ubiquitous protein that in both native and MLL-AF4 fusion types localizes to subnuclear compartments”,BloodNov. 15, 1998 92(10):3841-3847.
Milne et al., “MLL targets SET domain methyltransferase activity to Hox gene promoters”,Mol. Cell.Nov. 2002 10(5):1107-1117.
Mitelman, “Recurrent chromosome aberrations in cancer”,Mutat. Res.Apr. 2000 462(2-3):247-253.
Pui et al., “Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements”,LeukemiaApr. 2003 17(4):700-706.
Pui et al., “Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region”,LancetJun. 1, 2002 359(9321):1909-1915.
Reaman et al., “Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group”,J. Clin. Oncol.Feb. 1999 17(2):445-455.
Rowley, “The critical role of chromosome translocations in human leukemias”,Ann. Rev. Genet.1998 32:495-519.
Slany et al., “The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX”,Mol. Cell. Biol.Jan. 1998 18(1):122-129.
So et al., “Common mechanism for oncogenic activation of MLL by forkhead family proteins”,BloodJan. 15, 2003 101(2):633-639.
Yu et al., “Altered Hox expression and segmental identity in M11-mutant mice”,NatureNov. 30, 1995 378(6556):505-508.
Yu et al., “MLL, a mammalian trithorax-group gene, function as a transcriptional maintenance factor in morphogenesis”,Proc. Natl. Acad. Sci. USASep. 1, 1998 (18):10632-10636.
Zeisig et al., “Transcriptional activation is a key function encoded by MLL fusion partners”,LeukemiaFeb. 2003 17(2):359-365.
Gudibande Satyanarayana R.
Gupta Anish
Howson & Howson LLP
The Administrators of the Tulane Educational Fund
LandOfFree
Methods and compositions for treating leukemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating leukemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating leukemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3779649